Capricor Therapeutics Faces Class Action Lawsuit After 64% Stock Crash

Key Facts

In a move reflecting the high legal risks within the biotech sector, Capricor Therapeutics is facing a class action lawsuit accusing the company and its executives of securities fraud. The lawsuit alleges that the firm made misleading statements regarding the clinical data for its product, Deramiocel, and the integrity of its Biologics License Application. The emergence of these allegations has severely damaged investor confidence and triggered a massive sell-off.

According to reports, the company's stock crashed by 64% following the announcement of clinical data related to Deramiocel, leading to significant losses for shareholders. This legal action, led by Bleichmar Fonti & Auld LLP, places additional pressure on the company's financial stability and market credibility, especially after clinical evidence reportedly failed to support the efficacy of the proposed treatment.

As of August 25, 2026, updated price levels for the instrument are unavailable in the current database, leaving the stock's immediate direction dependent on further legal developments. Traders in the US market are also looking toward the FOMC minutes scheduled for August 19, 2026, which may influence broader risk appetite for high-growth sectors like biotechnology.